From left: Prof Luke O’Neill, independent non-executive director and scientific advisor at Poolbeg Pharma; Ian O’Connell, chief financial officer; Jeremy Skillington, chief executive; and Cathal Friel, non-executive chairman. Glandore managing director Michael Kelly has increased his stake in Cathal Friel’s Poolbeg Pharma to nearly 5 per cent, new stock exchange filings show.
His total stake in Poolbeg is now worth around £2.8 million, as its shares have risen in price to closer to 12 pence per share. The recent acquisition has made him the second largest individual shareholder in Poolbeg, after its founder, Mr Friel.An attempt to buy the next election with a giveaway budget would be a gross miscalculationMr Kelly is the managing director of Glandore, a company that offers co-working hubs for tech companies in Dublin and Belfast.
Mr Friel recently stepped down as chief executive to be replaced by Jeremy Skillington, and now serves as executive chairman. In a recent interview with the Business Post, Mr Skillington said the company could reach a €1 billion valuation.
Source: News Formal (newsformal.com)
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: businessposthq - 🏆 8. / 71 Read more »
Source: IrishTimes - 🏆 3. / 98 Read more »
Source: IrishTimes - 🏆 3. / 98 Read more »
Source: IrishTimes - 🏆 3. / 98 Read more »
Source: IrishTimes - 🏆 3. / 98 Read more »
Source: IrishTimes - 🏆 3. / 98 Read more »